Exact Sciences’ (NDAQ: EXAS) history is a tale of two halves. Founded in 1995 in Marlborough, Massachusetts, “Exact,” as the company is known, went public in 2001 but struggled to find its footing, ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Exact Sciences picked up the Oncotype DX GPS test in 2019—as well as Oncotype tests in breast and colon cancer—through its acquisition of $2.8 Genomic Health, one of the largest medtech deals of that ...

MADISON, Wis., May 26, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today that it will present 15 abstracts at the ...

Exact Sciences started rolling out its Cologuard Plus test in late March, after obtaining FDA approval and Medicare coverage, as a long-awaited update to its flagship home colorectal cancer screening ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences (EXAS) stock crashed to a three-year low Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer test. The company already developed a blood-based ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

In an article published that morning and updated in the afternoon, Bloomberg reported that pharmaceutical sector mainstay Abbott Laboratories appears to be on the brink of acquiring Exact Sciences.

Test Identifies Tumor DNA and RNA Alterations to Help Guide Personalized Treatments for Patients Based on Their Cancer "The OncoExTra test substantially enhances our ability to characterize and ...